Effect of apolipoprotein E ?4 carrier status on cognitive response to acetylcholinesterase inhibitors in patients with Alzheimer’s disease: A systematic review and meta-analysis
Dementia and Geriatric Cognitive Disorders Jul 27, 2018
Cheng YC, et al. - Researchers explored the link between treatment response with acetylcholinesterase inhibitors (AChEIs) and the apolipoprotein E ?4 (APOE ?4) carrier status through a systematic review and meta-analysis. They involved clinical studies with Alzheimer’s disease (AD) patients reporting APOE ?4 genotype in this analysis. In patients with AD, APOE ?4 carrier status had no considerable impact on the treatment response to AChEIs. Compared with placebo, irrespective of APOE ?4 carrier status, AChEIs had a positive therapeutic effect.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries